Compare CubeSmart (CUBE) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Johnson & Johnson — how do they compare? CubeSmart trades at $37.56 (market cap $8.38B), while Johnson & Johnson trades at $256.52 (market cap $622.84B). The key difference: Johnson & Johnson is far larger — about 74.3× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.69%). Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Johnson & Johnson for 129 Days on average.
| CUBE | JNJ | |
|---|---|---|
Market Cap | $8.38B | $622.84B |
Volume | 2,231,307 | 5,277,426 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $278.43 |
52-Week Low | $35.36 | $186.00 |
Typical Hold Time | 89 Days | 129 Days |
Enterprise Value | $11.91B | $651.12B |
Dividend Yield | 5.69% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.51, down 0.66% on the day, with a bearish technical signal but improving operational trends. The REIT reported Q2 2026 earnings beats and raised full-year guidance, though funds from operations slightly missed estimates. Valuation ratios like P/E of 25.33 and P/S of 7.48 are elevated, while profitability remains solid with a 29.41% net income margin. Recent news highlights institutional buying and debates on REIT valuations amid AI sector shifts.
Outlook is mixed: analyst consensus targets $44.00 with a 'Buy' lean, but technicals and macroeconomic headwinds pose risks. The stock offers a 5.4% dividend yield, yet same-store NOI declines and high debt levels warrant caution. Upside depends on sustained occupancy gains and moderating supply pressures in the self-storage sector.
Johnson & Johnson (JNJ) trades at $256.48, up 0.67% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net income margin and 25.74% ROE, though valuation metrics appear elevated with P/E of 29.98. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales and Q3 earnings anticipation.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and elevated valuation. Analyst consensus targets $286.53 (11.7% upside) with 52.5% buy ratings. Key risks include biosimilar competition for Stelara and debt-to-asset ratio increase to 24.06% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
